Table 4:
Miscellaneous Linear AMP Yield and PurityA
| AMP | Length (AA) | Avg. MW (Da) | Crude Yield (mg) | Crude Purity % (RTE) | Crude Loaded (mg) | Pure Yield (mg) | Recovery % | Purity % (RTE) |
|---|---|---|---|---|---|---|---|---|
| Buforin I | 39 | 4250.9 | 102 | 28 (22.2) | 102 | 6.0 | 21 | >99 (20.9) |
| CalciterminB | 15 | 1688.9 | 57 | 82 (14.9) | 48 | 13 | 33 | 75 (15.4) |
| β-Casein 197 | 17 | 2005.3 | 39 | 53 (28.5) | 39 | 14 | 68 | 98 (28.1) |
| Dermcidin | 47 | 4705.4 | 126 | 32 (38.1) | 126 | 11 | 27 | 88 (37.3) |
| GHH20 | 21 | 2417.5 | 80 | 34 (15.3) | 80 | 8.5 | 31 | 55 (15.2) |
| hGAPDHB | 31 | 3186.7 | 94 | 61 (28.1) | 52 | 35 | >99% | 80 (28.1) |
| KDAMP 19-mer | 19 | 1767.0 | 57 | 37 (18.9) | 57 | 17 | 81 | 85 (18.6) |
| PDC213 | 14 | 1471.7 | 31 | 70 (20.9) | 31 | 12 | 55 | >99 (20.8) |
| Salusin β | 20 | 2342.8 | 17 | 62 (38.4) | 17 | 8.0 | 76 | 88 (38.5) |
| Salvic | 46 | 5258.1 | 21 | 45 (54.4) | 21 | n/a | n/a | n/a |
| SgI-29 | 29 | 3377.7 | 104 | 67 (11.5) | 104 | 26 | 37 | 98 (11.4) |
| SgII Peptide AB | 29 | 3309.7 | 95 | 65 (15.0) | 52 | 6.1 | 18 | 79 (15.3) |
| Cathepsin G (1–5)C | 5 | 514.6 | 39 | 90 (14.3) | n/a | n/a | n/a | n/a |
| Ubiquicidin | 59 | 6647.8 | 117 | 61 (19.7) | 117 | 17 | 24 | 98 (9.1)D |
| Avg. | 27.9 | 3067.4 | 70 | 56 | 65 | 14 | 47 | 87 |
A
Characterization in Supplementary Figures 30–43. All synthesized on a 3rd Generation flow synthesizer set for speed and purified by RPFC Method 2 unless otherwise specified.
B
Purified by RPFC Method 1.
C
Synthesized on a 4th Generation flow synthesizer set for length.
D
Derived from HPLC Method 3 (30-minutes); crude characterized with HPLC Method 1 (60-minutes).
E
RT = retention time in minutes.